Some Chinese attendees said they are not yet affected but maybe while others said they weren't affected and that the trade impasse was likely to turn the attention of the biotech companies to Europe. Chinese pharma wouldn't be affected.
The deal will bring the CAR-T therapy to China's burgeoning market, but it faces competition from Gilead's Yescarta - manufactured under a JV with Fosun - and also homegrown products.
In today’s healthcare landscape, your choice of medical billing partner directly impacts your bottom line. What are the best medical billing outsourcing companies, and which one is right for you?